<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11237379</article-id><article-id pub-id-type="pmc">2363793</article-id><article-id pub-id-type="pii">6691637</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1637</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Doz</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gentet</surname><given-names>J C</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Pein</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frappaz</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chastagner</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Moretti</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vassal</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Arditti</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Tellingen</surname><given-names>O Van</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Iliadis</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Catalin</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departement d'Oncologie P&#x000e9;diatrique, Institut Curie, 26 rue d'Ulm, Paris, 75231 Cx 05</aff><aff id="aff2"><label>2</label>Service d'Oncologie P&#x000e9;diatrique, CHU La Timone, Bd J. Moulin 13005 Marseille</aff><aff id="aff3"><label>3</label>D&#x000e9;partement d'Oncologie P&#x000e9;diatrique, Institut Gustave Roussy Rue C. Desmoulins, 94800 Villejuif Cx</aff><aff id="aff4"><label>4</label>Service d'Oncologie p&#x000e9;diatrique, Centre L&#x000e9;on B&#x000e9;rard, 28 rue La&#x000eb;nnec 69000, Lyon</aff><aff id="aff5"><label>5</label>Service d'H&#x000e9;mato-canc&#x000e9;rologie P&#x000e9;diatrique, CHU Nancy, H&#x000f4;pital d'Enfants de Brabois, 5 all&#x000e9;e du Morvan, 54500 Vandoeuvreles Nancy</aff><aff id="aff6"><label>6</label>Centre anti-poison, 249 Bd Sainte Marguerite, Marseille, 13009</aff><aff id="aff7"><label>7</label>Department of Clinical Chemistry, The Netherlands Cancer Institute, Louwesweg 6, Amsterdam, 1066 CX</aff><aff id="aff8"><label>8</label>Facult&#x000e9; de Pharmacie, 27 av. J. Moulin, Marseille, 13385 Cx 051</aff><pub-date pub-type="ppub"><month>03</month><year>2001</year></pub-date><volume>84</volume><issue>5</issue><fpage>604</fpage><lpage>610</lpage><history><date date-type="received"><day>16</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The maximum tolerated dose of paclitaxel administered by 24-hour continuous infusion in children is known. Short infusion might offer equivalent antitumour efficacy and reduced haematological toxicity, without increasing the allergic risk. Our aims were to determine the maximum tolerated dose and the pharmacokinetics of paclitaxel in children when administered in 3-h infusion every 3 weeks. Patients older than 6 months, younger than 20 years with refractory malignant solid tumours were eligible when they satisfied standard haematological, renal, hepatic and cardiologic inclusion criteria with life expectancy exceeding 8 weeks. Paclitaxel was administered as a 3-hour infusion after premedication (dexamethasone, dexchlorpheniramine). Pharmacokinetic analysis and solvent assays (ethanol, cremophor) were performed during the first course. 20 courses were studied in 17 patients; 4 dosage levels were investigated (240 to 420&#x02008;mg/m<sup>2</sup>). No dose-limiting haematological toxicity was observed. Severe acute neurological and allergic toxicity was encountered. One treatment-related death occurred just after the infusion at the highest dosage. Delayed peripheral neurotoxicity and moderate allergic reactions were also encountered. Pharmacokinetic analysis showed dose-dependent clearance of paclitaxel and elevated blood ethanol and Cremophor EL levels. Although no limiting haematological toxicity was reached, we do not recommend this paclitaxel schedule in children because of its acute neurological toxicity. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>paclitaxel</kwd><kwd>short-term infusion</kwd><kwd>phase 1</kwd><kwd>children</kwd></kwd-group></article-meta></front></article>


